By combining the long experience of SmithKline Beckman with the scientific expertise of Nova Pharmaceutical, the two drug companies hope to develop new therapies with which to treat central nervous system diseases. Under a partnership announced last month and awaiting stockholder approval, SmithKline Beckman would specifically target $49 million over the next seven years for central nervous system research performed by the Baltimore company (The Scientist, May 16, 1988, page 1). Solomon Snyder, who founded Nova in 1982 and is director of the department of neuroscience at Johns Hopkins University, will be chairman of the collaboration. In addition, a second partnership has been formed by the two companies, this one to develop bradykinin antagonist compounds for the treatment of allergies, cold symptoms, and the like.
By the end of the summer, a high school somewhere in the United States is going to get quite a present—one that thousands of industry ...
